News and Trends 11 Jan 2018
German Biotech Gets FDA Approval to Start an Ulcerative Colitis Phase II Study
The FDA will allow Immunic Therapeutics to commence a Phase II clinical trial to test its oral investigational drug, IMU-838, for the treatment of ulcerative colitis. Immunic Therapeutics, which closed a €31M Series A last September, specializes in the development of drugs for the treatment of chronic inflammatory diseases. At the moment, the company has two ongoing […]